Clinical trials: Overweight/Obese Population
Obesity, Overweight
A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes
The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who…
- Trial name
- NCT07890376
- Testing
- LY4086940
- Where
- 46 sites in United States, Argentina
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus
Investigate the Efficacy and Safety of GSK1070806 in Obese Subjects With T2DM
GSK1070806 is a humanised IgG1/kappa antibody which is directed against the soluble cytokine interleukin-18 (IL-18). The aims of this placebo controlled study are to evaluate the efficacy, safety, tolerability, pharmacokinetics…
- Trial name
- T2DM (NCT01648153)
- Testing
- GSK1070806
- Where
- 13 sites in Spain, United Kingdom
- Volunteers
- 37 people
- Sponsor
- GlaxoSmithKline
Obesity
Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet
1. To evaluate the effect of S-2367 on body weight when administered following a 6-week placebo lead-in period and then a 54-week 800 kilocalorie deficit reduced calorie diet compared to placebo in healthy obese male and female…
- Trial name
- NCT00747929
- Testing
- S-2367 800 mg, S-2367 1600 mg, Reduced Calorie Diet
- Where
- 38 sites in United States
- Volunteers
- 724 people, healthy volunteers welcome
- Sponsor
- Shionogi
Obesity
Effect of Tesofensine on Energy Balance in Humans.
Purpose: To evaluate the effect of tesofensine on energy balance
- Trial name
- NCT00428415
- Testing
- Tesofensine
- Where
- Denmark
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- NeuroSearch A/S
Obesity
A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-06882961) for the potential treatment of obesity.
- Trial name
- NCT04707313
- Testing
- PF-06882961 (Cohorts 1 and 2), PF-06882961 (Cohort 3)
- Where
- 41 sites in United States, Canada and 2 more
- Volunteers
- 628 people
- Sponsor
- Pfizer
Obesity, Overweight
Current Status of Cardiovascular Diseases in Chinese Overweight/ Obesity Population: An Epidemiological Study (COPE）
This study is testing how overweight and obesity affect cardiovascular disease (CVD) prevalence, risk factors, and mortality among Chinese adults using nationally representative CCDRFS (China Chronic Disease and Risk Factor…
- Trial name
- COPE (NCT07358052)
- Testing
- No treatment given
- Where
- 2 sites in China
- Volunteers
- 551,931 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA) being developed for chronic weight…
- Conditions
- Obesity, Overweight, Type 2 Diabetes Mellitus (T2DM)
- Trial name
- NCT07670416
- Testing
- Enicepatide
- Where
- 21 sites in China
- Volunteers
- 300 people
- Sponsor
- Hoffmann-La Roche
Obesity, Hyperlipidemia
A Study on Efficacy and Safety of Topiramate in Treatment of Obese Subjects With Dyslipidemia
The purpose of this study is to compare the efficacy and safety of daily topiramate versus placebo for the treatment of obese subjects with dyslipidemia.
- Conditions
- Obesity, Hyperlipidemia, Hypertriglyceridemia
- Trial name
- NCT00231621
- Testing
- topiramate
- Volunteers
- 179 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Obesity
Safety and Efficacy of APD356 in the Treatment of Obesity
This is a research study of an investigational drug, APD356, a novel, selective 5-HT2c receptor agonist, in clinical development as a potential treatment for obesity.
- Trial name
- NCT00116740
- Testing
- APD356
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Obesity and Diabetes Mellitus, Type 2
A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus
The purpose of this study is to assess the effects of JNJ-64565111 compared with placebo in severely obese Type 2 Diabetes Mellitus (T2DM) participants after 12 weeks of treatment on: the percentage change in body weight from…
- Trial name
- NCT03586830
- Testing
- JNJ-64565111 Dose Level 1, JNJ-64565111 Dose Level 2, JNJ-64565111 Dose Level 3
- Where
- 27 sites in United States
- Volunteers
- 196 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes Mellitus, Type 2
A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes
The primary objective is to demonstrate, after 52 weeks of treatment, the non-inferiority of rimonabant 20 mg once daily (od) versus glimepiride od in reducing glycosylated haemoglobin (HbA1c) in overweight/obese patients with…
- Trial name
- ALLEGRO (NCT00449605)
- Testing
- Rimonabant, Glimepiride, Metformin
- Where
- 15 sites in United States, Chile and 12 more
- Volunteers
- 508 people
- Sponsor
- Sanofi
Obesity
A Comparison of the Metabolic Effects of Fructose, Glucose, High Fructose Corn Syrup and Sucrose at Normal Population Consumed Levels in Adults Aged 20-60 Years Old
The purpose of this study is to investigate the acute and chronic effects of consumption fructose containing sugars and glucose in a real word setting when consumed in a manner and amount typical in the American diet.
- Trial name
- NCT01797042
- Testing
- Dietary Compliance
- Where
- United States
- Volunteers
- 366 people, healthy volunteers welcome
- Sponsor
- Rippe Lifestyle Institute
Morbid Obesity
A Study of Clinical Outcomes of the REALIZE Adjustable Gastric Band-C
The purpose of this study is to evaluate the results patients are obtaining with the Realize™ Adjustable Gastric Band-C during the first 24 months after surgery.
- Trial name
- NCT00999661
- Where
- 7 sites in United States
- Volunteers
- 231 people
- Sponsor
- Ethicon Endo-Surgery
Overweight, Obesity
Effect of GSP3 on Body Weight in Overweight and Obese Subjects
The FLOW (First Loss Of Weight) study is designed to assess the effects of repeated administration of GSP3, an investigational product, on body weight.
- Trial name
- FLOW (NCT03008954)
- Testing
- GSP3, Avicel (modified Cellulose)
- Where
- 5 sites in Czechia, Denmark and 1 more
- Volunteers
- 128 people
- Sponsor
- Gelesis, Inc.
Triglycerides, Weight Gain Trajectory
Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists
The goal of this clinical trial is to learn if drug RDX-002 works to treat high levels of fat (known as triglycerides, or TGs) in the blood in adults. It will also learn about the safety of drug RDX-002.
- Conditions
- Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated
- Trial name
- NCT06640972
- Testing
- RDX-002
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Response Pharmaceuticals
Type 2 Diabetes, High Blood Pressure
Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients
Evaluation of safety, tolerability and superiority of RK-01, a valsartan plus celecoxib dual add-on to metformin-HCL XR over metformin in newly diagnosed and obese adult type 2 diabetes patients with high blood pressure…
- Conditions
- Type 2 Diabetes, High Blood Pressure, Arthritis, Obesity
- Trial name
- RESILIENCE (NCT03686657)
- Testing
- Metformin, Val, Cel and Met XR Low, Val, Cel and Met XR High
- Where
- United States
- Sponsor
- ARKAY Therapeutics
Overweight , Obesity
A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)
This study will evaluate the percentage change in body weight from baseline and proportion of subjects achieving ≥ 5% weight loss from baseline after 52 weeks of treatment with Zovaglutide in subjects with overweight/obesity.
- Trial name
- NCT07230119
- Testing
- Zovaglutide dose 1, Zovaglutide dose 2
- Where
- 45 sites in China
- Volunteers
- 755 people
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Childhood Obesity, Prediabetes
Clinical Utility of SUDOSCAN in the Pediatric Population
The main purpose of this study is to evaluate whether SUDOSCAN is a valid, accurate clinical device for the the determination of sweat gland function in the pediatric population.
- Conditions
- Childhood Obesity, Prediabetes, Diabetes
- Trial name
- NCT02216201
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Impeto Medical
Diabetes Mellitus and Heart Failure
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
This was a dose-finding study to evaluate the efficacy, safety and tolerability of 3 different doses of LIK066 compared to placebo or empagliflozin in T2DM patients with heart failure
- Trial name
- NCT03152552
- Testing
- LIK066, Empagliflozin
- Where
- 106 sites in United States, Argentina and 22 more
- Volunteers
- 125 people
- Sponsor
- Novartis Pharmaceuticals
Overweight, Obese
A Pharmacokinetic Study of HDM1005 Injection in Participants With Impaired Renal Function and Healthy Participants
The purpose of this study is to evaluate the pharmacokinetic profile and safety of a single subcutaneous injection of HDM1005 solution in participants with impaired kidney function compared to healthy participants.
- Trial name
- NCT07559240
- Testing
- HDM1005
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.